Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer
Overview
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving epidermal growth factor receptor inhibitors may help doctors understand the effect of epidermal growth factor receptor inhibitors on magnesium levels in the body. PURPOSE: This laboratory study is looking at the effect of epidermal growth factor receptor inhibitors on magnesium homeostasis in patients with cancer.
Full Title of Study: “Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on Magnesium Homeostasis”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: March 2008
Detailed Description
OBJECTIVES: – Determine the effects of EGFR inhibitors on magnesium homeostasis in patients with cancer. OUTLINE: This is a pilot study. Patients undergo blood and urine sample collection at baseline and at 2, 4, and 8 weeks during treatment. After finishing treatment, patients are followed periodically for up to 10 weeks.
Interventions
- Other: laboratory biomarker analysis
- laboratory biomarker analysis
Clinical Trial Outcome Measures
Primary Measures
- Effects of EGFR inhibitors on magnesium homeostasis
- Time Frame: 8 weeks
Participating in This Clinical Trial
Inclusion Criteria
- Diagnosis of malignancy – Planning to receive therapy with an inhibitor of the EGFR pathway (either on or off a clinical trial and may be monotherapy or combined with other therapies) – Normal serum magnesium level Exclusion Criteria:
- Glomerular filtration rate ≥ 60 mL/min – No severe underlying renal dysfunction – Normal serum potassium and calcium level – No history of primary or secondary hyperparathyroidism PRIOR CONCURRENT THERAPY: – No prior EGFR pathway inhibitor
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Collaborator
- National Cancer Institute (NCI)
- Provider of Information About this Clinical Study
- Principal Investigator: Laura W. Goff, MD, Assistant Professor of Medicine; Associate Director, Hematology/Oncology – Vanderbilt-Ingram Cancer Center
- Overall Official(s)
- Laura Goff, MD, Principal Investigator, Vanderbilt-Ingram Cancer Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.